Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
about
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysisCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewTherapeutic challenges in renal cell carcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesWhich Metrics Are Appropriate to Describe the Value of New Cancer Therapies?Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisResponse Evaluation of Chemotherapy for Lung Cancer.Novel immunotherapy in metastatic renal cell carcinoma.Study of the effectiveness of first-line treatment in renal cell carcinoma.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyPersonalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTNovel agents in renal carcinoma: a reality check.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinomaA combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyMetastasis to the parotid region as an initial presentation of renal cell carcinoma: A case report.Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinomaVascular disruption in combination with mTOR inhibition in renal cell carcinoma.Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma.Is adoptive T-cell therapy for solid tumors coming of age?Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.Targeted therapies in metastatic renal cell carcinoma: overview of the past year.Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.Temsirolimus: a safety and efficacy review.Emerging immunotherapies for renal cell carcinoma.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
P2860
Q26746200-467FBE43-1AB5-4747-929F-4FB824FBAEA0Q26774515-879AD0AD-4E2A-4BAD-8D27-0D4949E815EAQ26796702-D2EEF14A-0BB8-4469-937F-EB3001CAC146Q26852437-A974C6DF-E089-4212-B44A-41FA397937BBQ26858853-58990C6C-F574-4AD6-8F79-795C4B48D256Q30317831-B1C3FD53-A90C-4914-B1C0-CED3D14E2047Q31085777-97AF78C3-C99A-48E9-A552-B37BE20434EAQ33430139-0130E004-D389-48F8-9FE6-CA1E5A941BB7Q33567345-1DD934F3-9DB1-4F2E-8DD6-72629ED9339EQ33863074-627D9524-6DA7-4A71-A6C6-A92CAB058F78Q34265673-F6CDEBF8-8DE0-4AB9-A152-68C0767F56CEQ34351372-09FC1319-6050-43E6-B459-8258EEC1BC53Q34661185-3CE36D99-3303-4EC5-ADDD-BF7F209DD003Q34978199-F920A3AF-88F0-4BB7-B472-DDA640FEDDF0Q35080143-204C2979-89EB-473B-9872-66B27D259276Q36015295-21E296F7-AE25-4F8D-BB11-0907689CEECFQ36061173-344DD643-9746-47A3-84D3-452F9EBD1BC3Q36084341-2C8D134A-F6B0-4429-B93E-A76C3BB01EF0Q36093104-80909F6E-D92F-47FC-A9CB-60385230375CQ36356265-4CED7A84-F29E-45BF-8918-1A2A42944951Q36546814-3C2C9FEE-753E-4B7E-9332-D68323648640Q36621580-2216BDE2-CE4D-4353-9CF9-CBB6BB46AB1EQ37096469-4ABC40CC-3276-46E7-BB2E-90BFE00485F0Q37154148-EDBD558E-30BD-4447-8E0B-C86F1D6FC4C0Q37294895-397BF863-EDE0-4066-B7CB-630E64DD15EFQ37403056-09E15849-2765-4D52-BEF4-75579C0825BFQ37403763-774B76F1-542A-4EB9-B373-AA517FD7BC75Q37470131-92619208-C0CB-429A-8CAA-F58A2C4996EEQ37704676-8901B6F8-3B10-4DEE-A725-7C6FC3DA48A2Q37712156-74C90863-E3AA-4A66-9542-D9C9F4E2780BQ37909004-97629E57-6913-4038-854B-4A3EEE06533FQ37952233-EA75DB03-A8D7-43C8-A683-AAC5F2832D8DQ37964565-F0293BF5-6E36-472E-8D98-0204B6AF3020Q37993393-DB0630E6-DE9B-4134-ABFD-26C8C6B1E591Q38031941-A2A55174-A7D8-491E-A512-75843CEE5C35Q38037491-A7E72122-F790-45FC-885B-C15B5124E73BQ38048822-09ACF911-A825-42B0-AA24-960DFD2464A2Q38068584-6406224B-CA0E-4693-9A8C-E44840A57B0CQ38068922-FADEAC8E-274F-41F2-BC3E-D73CF56ED939Q38172644-AB5A1FDD-80AA-4281-81ED-3BE1E1D85FCE
P2860
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@ast
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@en
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@nl
type
label
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@ast
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@en
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@nl
prefLabel
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@ast
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@en
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@nl
P2860
P1433
P1476
Targeted therapies for the tre ...... carcinoma: clinical evidence.
@en
P2093
Thomas E Hutson
P2860
P356
10.1634/THEONCOLOGIST.2011-S2-14
P478
16 Suppl 2
P577
2011-01-01T00:00:00Z